Evidence map›Paper›PMID 33024200›Full record

ArticleScientific reports2020

Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer.

Constance Le Goux, Sophie Vacher, Anne Schnitzler, Nicolas Barry Delongchamps, Marc Zerbib, Michael Peyromaure, Mathilde Sibony, Yves Allory, Ivan Bieche, Diane Damotte and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. The miRNome of canine invasive urothelial carcinoma.Frontiers in veterinary science · 2022
    Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Constance Le GouxPharmacogenomics Unit, Department of Genetic, Curie Institute, Paris, France. constance.legoux@gmail.com.
Sophie VacherPharmacogenomics Unit, Department of Genetic, Curie Institute, Paris, France.
Anne SchnitzlerPharmacogenomics Unit, Department of Genetic, Curie Institute, Paris, France.
Nicolas Barry DelongchampsDepartment of Urology, Cochin Hospital, Paris Descartes University, Paris, France.
Marc ZerbibDepartment of Urology, Cochin Hospital, Paris Descartes University, Paris, France.
Michael PeyromaureDepartment of Urology, Cochin Hospital, Paris Descartes University, Paris, France.
Mathilde SibonyDepartment of Pathology, Cochin Hospital, Paris Descartes University, Paris, France.
Yves AlloryDepartment of Pathology, Curie Institute, Paris, France.
Ivan BiechePharmacogenomics Unit, Department of Genetic, Curie Institute, Paris, France.
Diane DamotteDepartment of Pathology, Cochin Hospital, Paris Descartes University, Paris, France.
Geraldine PignotDepartment of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France.
Institut Curie · FRHôpital Cochin · FRDélégation Paris 5 · FRInstitut Cochin · FRInstitut Paoli-Calmettes · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study evaluated the prognostic value of a panel of 29 oncogenes derived from the analysis of The Cancer Genome Atlas (TCGA data) or from the recent literature on bladder tumors on a well-characterized series of muscle-invasive bladder cancer (MIBC) and non-MIBC (NMIBC) samples and tried to identify molecular prognostic markers. Mutations of HRAS, FGFR3, PIK3CA and TERT were found in 2.9%, 27.2%, 14.9% and 76.7% of tumor samples, respectively. Concerning NMIBC, on multivariate analysis, RXRA and FGFR3 levels were associated with recurrence-free survival (RFS) (p = 0.0022 and p = 0.0069) and RXRA level was associated with progression to muscle-invasive disease (p = 0.0068). We identified a 3-gene molecular signature associated with NMIBC prognosis. FGFR3 overexpression was associated with reduced response to Bacillus Calmette-Guerin treatment (p = 0.037). As regards MIBC, on multivariate analysis, ERCC2 overexpression was associated with RFS (p = 0.0011) and E2F3 and EGFR overexpression were associated with overall survival (p = 0.014 and p = 0.035). RT-PCR findings were confirmed by IHC for FGFR3. Genomic alterations in MIBC revealed in TCGA data also concern NMIBC and seem to be associated with prognosis in terms of recurrence and progression. Correcting these alterations by targeted therapies seems a promising pharmacological approach.

Indexed as

Databases, GeneticOncogenesAgedBCG VaccineClass I Phosphatidylinositol 3-KinasesDisease ProgressionFemaleGene ExpressionHumansMaleMiddle AgedMutationNeoplasm InvasivenessNeoplasm Recurrence, LocalPrognosisProto-Oncogene Proteins p21(ras)BCG VaccineClass I Phosphatidylinositol 3-KinasesFGFR3 protein, humanHRAS protein, humanPIK3CA protein, humanProto-Oncogene Proteins p21(ras)Receptor, Fibroblast Growth Factor, Type 3Retinoid X Receptor alphaRXRA protein, humanTelomeraseTERT protein, human

Identifiers

PMID33024200
PMCPMC7538919
OpenAlexW3092330531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.